Psychedelic Science Institute Launches Clinical Trial Sites in Los Angeles

Experienced Team Opens TRIP Clinics in Santa Monica and Hollywood to Advance Psychedelic Medicine and Mental Health Care

LOS ANGELES, July 1, 2025 /PRNewswire/ -- Psychedelic Science Institute (PSI), a next-generation clinical trial and treatment network, announced its official launch today with two clinics in Santa Monica and Hollywood, California. These "TRIP Clinics" (Treatment & Research in Psychedelics) serve as hubs for industry-sponsored and investigator-initiated clinical trials of psychedelic-assisted therapies for a range of mental health and neuroscience conditions.

Formed through the strategic merger of Pacific Neuroscience Institute's TRIP Center and the California Center for Psychedelic Therapy, PSI brings together a multispecialty team with 30 years of combined leadership in neuroscience, psychotherapy, and psychedelic research. The founding team and clinics have collectively enrolled over 90 patients across 10 clinical trials of psychedelic compounds targeting conditions including depression, anxiety, PTSD, and alcohol use disorder. They have also delivered over 10,000 ketamine-assisted therapy sessions to date.

"As neuroplastogens, psychedelics may offer the greatest potential in decades to transform psychiatry and neuroscience," said Daniel Kelly, MD, PSI President & CEO. "Our TRIP Clinics will rigorously assess these paradigm-shifting treatments in collaboration with industry and academic partners."

Backed by $1.2 million in early philanthropic support, PSI launches with a dual mission: to accelerate the development of FDA-approved psychedelic treatments and to build a scalable, accessible model of transformative mental health care. PSI's clinical trials focus on substances such as psilocybin, LSD, MDMA, and 5-MeO-DMT, while offering ketamine-assisted psychotherapy under established protocols.

"We are thrilled to launch PSI as a partnership of two of California's most experienced and longest-running psychedelic research and care clinics," said Brooke Balliett, LMFT, PSI Chief Operating Officer. "We look forward to expanding our services across our diverse Los Angeles communities and beyond."

Through the nonprofit, Psychedelic Innovation Fund, PSI is also investing in public education, clinician training, and infrastructure to support the safe and ethical growth of the field.

"PSI is built to meet this moment in psychedelic research," said Keith Heinzerling, MD, PSI Chief Medical & Science Officer. "We bring real-world experience, a highly skilled clinical operations team, and a deep commitment to scientific rigor and patient safety."

To partner on clinical trials or learn more, visit: www.psychedelicsci.com
Contact: Greg Kearns, 410-409-8913, [email protected]

View original content:https://www.prnewswire.com/news-releases/psychedelic-science-institute-launches-clinical-trial-sites-in-los-angeles-302495014.html

SOURCE Psychedelic Science Institute